A detailed history of Bayesian Capital Management, LP transactions in Catalent, Inc. stock. As of the latest transaction made, Bayesian Capital Management, LP holds 8,000 shares of CTLT stock, worth $507,840. This represents 0.06% of its overall portfolio holdings.

Number of Shares
8,000
Previous 6,400 25.0%
Holding current value
$507,840
Previous $359,000 34.82%
% of portfolio
0.06%
Previous 0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$56.16 - $60.96 $89,856 - $97,536
1,600 Added 25.0%
8,000 $484,000
Q2 2024

Aug 14, 2024

BUY
$53.58 - $57.02 $342,912 - $364,928
6,400 New
6,400 $359,000
Q4 2023

Feb 14, 2024

SELL
$32.18 - $46.57 $759,448 - $1.1 Million
-23,600 Reduced 57.37%
17,533 $787,000
Q3 2023

Nov 14, 2023

BUY
$44.2 - $50.2 $1.82 Million - $2.06 Million
41,133 New
41,133 $1.87 Million
Q4 2022

Feb 14, 2023

SELL
$41.39 - $81.0 $8,278 - $16,200
-200 Reduced 1.85%
10,627 $478,000
Q3 2022

Nov 14, 2022

BUY
$72.36 - $113.1 $783,441 - $1.22 Million
10,827 New
10,827 $783,000
Q3 2020

Nov 12, 2020

SELL
$72.74 - $92.5 $952,966 - $1.21 Million
-13,101 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$48.02 - $79.04 $307,328 - $505,856
6,400 Added 95.51%
13,101 $960,000
Q1 2020

May 15, 2020

BUY
$36.95 - $62.95 $247,601 - $421,827
6,701 New
6,701 $348,000
Q3 2019

Nov 13, 2019

SELL
$47.45 - $58.05 $351,462 - $429,976
-7,407 Closed
0 $0
Q2 2019

Aug 13, 2019

SELL
$39.26 - $54.21 $106,002 - $146,367
-2,700 Reduced 26.71%
7,407 $402,000
Q1 2019

May 14, 2019

BUY
$29.84 - $43.92 $301,592 - $443,899
10,107 New
10,107 $410,000
Q4 2017

Feb 12, 2018

SELL
$37.27 - $43.02 $819,940 - $946,440
-22,000 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$33.75 - $41.67 $742,500 - $916,740
22,000
22,000 $878,000

Others Institutions Holding CTLT

About Catalent, Inc.


  • Ticker CTLT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 179,896,000
  • Market Cap $11.4B
  • Description
  • Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...
More about CTLT
Track This Portfolio

Track Bayesian Capital Management, LP Portfolio

Follow Bayesian Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bayesian Capital Management, LP with notifications on news.